Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Helmholtz Zentrum München | INDUSTRY |
| Charite University, Berlin, Germany | OTHER |
| Medical University of Vienna | OTHER |
Not provided
Not provided
Not provided
Not provided
In this mono-center pilot trial, surgical patients who are at high risk to be admitted to intensive care will be screened and asked for participation. We are going to take blood and muscle samples at respecified time points to do metabolic, histological and molecular testing.
Aim of the study is to investigate (1) changes of the blood metabolome in patients with ICUAW (intensive care unit acquired weakness) and (2) identify metabolic components who are responsible for ICUAW or can be used as marker for ICUAW.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intensive Care Patients | Postoperative high-risk patients who have been admitted to intensive care after surgery | ||
| Operative Control patients | Elective operative patients where control blood samples and muscle ultrasound will be measured. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Metabolomics | Blood Metabolome will be isolated from blood samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) using mass spectrometry. | a median of 14 days |
| Measure | Description | Time Frame |
|---|---|---|
| Muscle histology | Immunohistochemistry will be done in muscle samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) and correlation with blood metabolome changes. | a median of 14 days |
| Phosphoproteomics |
| Measure | Description | Time Frame |
|---|---|---|
| Identify possible predictors of muscle wasting in the blood metabolome preoperatively | Among the blood metabolome that will be measured, identify metabolites or combinations of metabolites whose high or low concentration(s) preoperatively associate(s) with the amount of muscle loss. These metabolites are candidate biomarkers that could be used to identify individuals at risk of large muscle wasting and may give further insights into the mechanisms of muscle wasting. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
mechanically ventilated postoperative high-risk patients who are admitted to intensive care
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Stefan J Schaller, MD | Contact | +4314040041020 | stefan.schaller@meduniwien.ac.at | |
| Marian Demitsch | Contact | +4314040041020 | aai-research@muv.ac.at |
| Name | Affiliation | Role |
|---|---|---|
| Stefan J Schaller, MD | Technical University of Munich | Principal Investigator |
| Hennig Wackerhage, PhD | Technical University of Munich | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical University of Vienna | Recruiting | Vienna | State of Vienna | 1090 | Austria |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D016638 | Critical Illness |
| D011115 | Polyneuropathies |
| D009135 | Muscular Diseases |
| D018908 | Muscle Weakness |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010523 | Peripheral Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Phosphoproteomics will be done in muscle samples using mass spectrometry. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) and correlation with blood metabolome changes.
| a median of 14 days |
| a median of 14 days |
| Identify possible predictors of muscle wasting in the blood metabolome at ICU admission | Among the blood metabolome that will be measured, identify metabolites or combinations of metabolites whose high or low concentration(s) at ICU admission associate(s) with the amount of muscle loss. These metabolites are candidate biomarkers that could be used to identify individuals at risk of large muscle wasting and may give further insights into the mechanisms of muscle wasting. | a median of 14 days |
| Klinikum rechts der Isar, School of Medicine, Technical University of Munich | Active, not recruiting | Munich | Bavaria | 81675 | Germany |
| Charité - Universitätsmedizin Berlin | Active, not recruiting | Berlin | State of Berlin | 10117 | Germany |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D009140 | Musculoskeletal Diseases |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |